Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Lymphoid 1

Conditions

TMB-H 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × IMC-001 × 1 year × Clear all
NCT04414163 2026-04-24

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

ImmuneOncia Therapeutics Inc.

Phase 2 Active not recruiting
23 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT06365840 2026-04-17

TMB-H

ImmuneOncia Therapeutics Inc.

Phase 2 Recruiting
30 enrolled
Other solid neoplasm

TMB-H

Data powered by HemOnc (CC BY 4.0) Colophon âš¡